Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Wolf

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Journal of Virology|March 27, 2009
Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogensPetra Mooij, Sunita S Balla-Jhagjhoorsingh, Niels Beenhakker, et al.
Plos One|July 24, 2008
Nod2 mediates susceptibility to Yersinia pseudotuberculosis in miceUlrich Meinzer, Sophie Esmiol-Welterlin, Frederick Barreau, et al.
Vaccine|May 27, 2008
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneSheena McCormack, Wolfgang Stöhr, Tristan Barber, et al.
Obstetrics and Gynecology|February 3, 2007
Predictors of neonatal outcome in early-onset placental dysfunctionAhmet A Baschat, Erich Cosmi, Catarina M Bilardo, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
Lancet (London, England)|March 10, 2015
2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trialChristoph C Lees, Neil Marlow, Aleid van Wassenaer-Leemhuis, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|November 3, 2025
Temporal Changes in Fetal and Maternal Parameters in Early-Onset Fetal Growth Restriction: A Multicenter, Retrospective Cohort StudyMette van de Meent, Ewoud Schuit, Wessel Ganzevoort, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|November 12, 2021
Longitudinal Doppler Assessments in Late Preterm Fetal Growth RestrictionBronacha Mylrea-Foley, Hans Wolf, Tamara Stampalija, et al.
BMJ Open|April 16, 2022
Perinatal and 2-year neurodevelopmental outcome in late preterm fetal compromise: the TRUFFLE 2 randomised trial protocolBronacha Mylrea-Foley, Jim G Thornton, Edward Mullins, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Journal of Virology|March 27, 2009
Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogensPetra Mooij, Sunita S Balla-Jhagjhoorsingh, Niels Beenhakker, et al.
Plos One|July 24, 2008
Nod2 mediates susceptibility to Yersinia pseudotuberculosis in miceUlrich Meinzer, Sophie Esmiol-Welterlin, Frederick Barreau, et al.
Vaccine|May 27, 2008
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneSheena McCormack, Wolfgang Stöhr, Tristan Barber, et al.
Obstetrics and Gynecology|February 3, 2007
Predictors of neonatal outcome in early-onset placental dysfunctionAhmet A Baschat, Erich Cosmi, Catarina M Bilardo, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
Lancet (London, England)|March 10, 2015
2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trialChristoph C Lees, Neil Marlow, Aleid van Wassenaer-Leemhuis, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|November 3, 2025
Temporal Changes in Fetal and Maternal Parameters in Early-Onset Fetal Growth Restriction: A Multicenter, Retrospective Cohort StudyMette van de Meent, Ewoud Schuit, Wessel Ganzevoort, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|November 12, 2021
Longitudinal Doppler Assessments in Late Preterm Fetal Growth RestrictionBronacha Mylrea-Foley, Hans Wolf, Tamara Stampalija, et al.
BMJ Open|April 16, 2022
Perinatal and 2-year neurodevelopmental outcome in late preterm fetal compromise: the TRUFFLE 2 randomised trial protocolBronacha Mylrea-Foley, Jim G Thornton, Edward Mullins, et al.
Pageof 18